Oncology · Medical Literature
[Articles] Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial
Abstract
A single, postoperative pirarubicin instillation after radical nephroureterectomy is an efficacious treatment with manageable adverse events to reduce recurrence in patients with upper tract urothelial carcinoma.
Clinical relevance
In patients with clinical stage 0a–III upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU), does a single early intravesical instillation of pirarubicin (30 mg within 24 hours postoperatively) improve relapse-free survival compared with observation alone? __SNAPSHOT__ {"studyDesign":"Multicentre, open-label, randomised, phase 3 superiority trial (JCOG1403) with two-stage registration","setting":"44 institutions within the Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG); Japan","sampleSize":"n=304 randomised (pirarubicin: n=153; observation: n=151); 352 enrolled at first registration, 348 underwent RNU","population":"Adults aged 20–80 years with previously untreated clinical stage 0a–III UTUC, ECOG performance status 0–1, and no prior or concurrent cystoscopic evidence of bladder cancer","intervention":"Single intravesical instillation of pirarubicin 30 mg in 30 mL, administered within 24 hours after radical nephroureterectomy and retained in the bladder for 30 minutes","comparator":"Observation (no intravesical instillation); patients with pT3/T4 or pN+ disease in both arms received adjuvant gemcitabine plus cisplatin (2 cycles, every 4 weeks)","primaryOutcome":"Relapse-free survival (RFS), analysed in the intention-to-treat population (all patients who underwent second registration)","followUp":"Median 4.3 years (IQR 3.4–5.1)","fundingSource":"Government/non-profit: Japan Agency for Medical Research and Development; National Cancer Centre Research and Development Fund, Japan"}
Key findings
The primary endpoint was met. Three-year relapse-free survival was 60.0% (95% CI 51.7–67.3) in the pirarubicin group versus 47.0% (95% CI 38.7–54.9) in the observation group — an absolute difference of 13.0 percentage points (calculated) — corresponding to a hazard ratio of 0.67 (90.96% CI 0.50–0.88; p=0.0066), indicating a statistically significant 33% relative reduction in the risk of relapse or death. NNT to prevent one relapse event at 3 years: approximately 7.7 (calculated; based on absolute risk difference of 13.0%). Secondary outcomes including intravesical relapse-free survival were improved, while non-intravesical relapse-free survival and overall survival did not show significant improvement — consistent with the mechanism of action being localised to the bladder compartment. The primary analysis was triggered after 153 events rather than the pre-specified 166 events; however, statistical significance was maintained across sensitivity analyses. A small proportion of patients in the pirarubicin group experienced grade 3 haematuria; overall adverse events were described as manageable. Specific grade 3–4 adverse event rates by type are not reported in the available abstract.
Practice implications
JCOG1403 provides the first phase 3 randomised evidence that a single, early postoperative intravesical instillation of pirarubicin reduces relapse-free events in patients with stage 0a–III UTUC following RNU. The absolute 3-year RFS benefit of ~13 percentage points and an HR of 0.67 are clinically meaningful in a cancer with historically high bladder recurrence rates (~20–50% at 5 years). Critically, the benefit appears to be driven by prevention of intravesical (bladder) relapse specifically; no significant improvement in non-intravesical RFS or overall survival was demonstrated, indicating this intervention does not alter systemic disease trajectory. The findings are directly applicable to the trial population: adult Japanese patients with stage 0a–III UTUC, ECOG PS 0–1, no concurrent bladder cancer, who have completed RNU. Generalisability to non-Japanese populations is uncertain. Patients with pT3/T4 or pN+ disease who concurrently receive adjuvant systemic chemotherapy were included; the independent contribution of pirarubicin in this subgroup cannot be precisely isolated. Eight randomised patients were ultimately found on pathology not to have urothelial carcinoma, a small but real misclassification risk attributable to the low preoperative ureteroscopy rate (37%). No head-to-head comparison with other intravesical agents (e.g., mitomycin C) was conducted. This summary is based on the published abstract; access to full trial data including complete safety tables, subgroup analyses, and overall survival data is required for a comprehensive evaluation. Practice change is supported by the strength of this phase 3 evidence, but clinicians should contextualise the OS-neutral finding and limited generalisability. __LIMITATIONS__ Open-label design precludes blinding of patients and clinicians; potential for differential ascertainment of recurrence events.,Exclusively Japanese cohort limits racial and ethnic generalisability; UTUC biology and surgical practice may differ internationally.,Primary analysis triggered at 153 events rather than the pre-specified 166 events, introducing a minor deviation from the original sample-size calculation; significance was maintained across sensitivity analyses.,Preoperative ureteroscopy performed in only 37% of participants; eight randomised patients were found on pathology not to have urothelial carcinoma, representing diagnostic misclassification.,No statistically significant improvement in non-intravesical RFS or overall survival was demonstrated — the clinical benefit is compartment-specific (bladder only).,No direct comparison with other intravesical chemotherapy agents (e.g., mitomycin C); superiority of pirarubicin over alternatives is unestablished.,Subgroup analyses were exploratory, not powered for interaction testing, and involved unadjusted multiple comparisons — should be interpreted with caution.,Pirarubicin is not approved or readily available in all countries, limiting direct applicability outside Japan.,Complete safety data (full grade 3–4 adverse event rates by category) not available from the abstract alone.,Surrogate endpoint concern: RFS improvement, while meaningful in preventing morbid bladder procedures, does not translate to a demonstrated overall survival benefit in this trial. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ JCOG1403 demonstrates that a single intravesical instillation of pirarubicin 30 mg administered within 24 hours of radical nephroureterectomy significantly improves 3-year relapse-free survival (60.0% vs. 47.0%; HR 0.67; p=0.0066) in patients with stage 0a–III UTUC, with a clinically meaningful absolute benefit of ~13 percentage points. The benefit is confined to prevention of intravesical (bladder) recurrence with no demonstrated improvement in overall survival, and the evidence base is restricted to a Japanese patient population. For centres where pirarubicin is available, this phase 3 trial provides sufficient evidence to adopt single early postoperative intravesical instillation as standard of care after RNU, consistent with the practice already supported by prior phase 2 data and EAU guideline recommendations for early postoperative intravesical chemotherapy.